Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database
Die Pharmazie · 01.12.2025 · 80 (11-12)
DOI: 10.31083/ph.2025.5660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 01.12.2025. Verfasst von T. Nagase und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Zolbetuximab, a monoclonal antibody against claudin-18.2 (CLDN18.2), improves outcomes in CLDN18.2-positive gastric cancer, but gastrointestinal adverse events—especially nausea and vomiting—are frequently reported. Using PMDA-JADER (April 2004–March 2025), we identified individual case safety reports (ICSRs) listing zolbetuximab as a suspected drug and defined the outcome with MedDRA-concordant preferred terms (nausea, vomiting, nausea and vomiting, retching). Within zolbetuximab reports, binary logistic regression with sex (male reference) and age (
Zitieren
APA
Nagase, T., & Shinozaki, K. (2025). Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database. Die Pharmazie, 80(11-12). https://doi.org/10.31083/ph.2025.5660
Vancouver
Nagase T, Shinozaki K. Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database. Die Pharmazie. 2025;80(11-12). doi:10.31083/ph.2025.5660
BibTeX
@article{Nagase2025,
author = {Nagase, T. and Shinozaki, K.},
title = {Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database},
journal = {Die Pharmazie},
year = {2025},
volume = {80},
number = {11-12},
doi = {10.31083/ph.2025.5660}
}
EUVIMED